CURRICULUM VITAE
Patricia Steinert PhD
Patricia Steinert PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Executive Scientific Director, Policy and Governance
Center for International Blood and Marrow Transplant Research (CIBMTR)
Department of Medicine
Division of Hematology and Oncology - Medicine
Executive Scientific Director, Policy and Governance
Center for International Blood and Marrow Transplant Research (CIBMTR)
OFFICE ADDRESS: |
Clinical Cancer Center |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
Phone: 414-805-0700 |
Fax: 414-805-0714 |
Email: psteinert@mcw.edu |
EDUCATION: |
08/1978 - 05/1982 BA, University of Wisconsin, Madison, WI |
08/1984 - 05/1987 MBA, University of Illinois, Chicago, IL |
08/2009 - 12/2012 PhD, University of Wisconsin, Milwaukee, WI |
10/2021 - 05/2022 Leadership Academy, Medical College of Wisconsin/University of Wisconsin Milwaukee, Milwaukee, WI |
FACULTY APPOINTMENTS: |
01/01/2022 - Present Associate Professor, Executive Scientific Director, CIBMTR, Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI 53202 |
ADMINISTRATIVE APPOINTMENTS: |
07/1989 - 02/1992 Associate Director Student Financial Aid, College of Medicine, Dean's Office, University of Illinois at Chicago, Chicago, IL |
02/1992 - 11/1994 Assistant Dean Informatics, College of Medicine, Dean's Office, University of Illinois at Chicago, Chicago, IL |
03/01/2013 - 12/31/2021 Executive Director, Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, CIBMTR, Medical College of Wisconsin, Milwaukee, WI., Milwaukee, WI |
08/2021 - Present Member, Institutional Review Board Committee #3, Medical College of Wisconsin, Milwaukee, WI 53202 |
01/2022 - Present Executive Scientific Director, Center for International Blood and Marrow Research, Medical College of Wisconsin, Milwaukee, WI 53202 |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
03/1995 - 03/1996 Research Project Manager, Louisiana Healthcare Review, Baton Rouge, LA |
06/2006 - Present Program Manager and Study Team Member, KGF Long Term Follow Up Study, Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI |
08/2013 - Present Member, Health Services Research Program, CIBMTR, National Marrow Donor Program, Minneapolis, MN |
AWARDS AND HONORS: |
2012 Phi Kappa Phi |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
06/1986 - 06/1990 National Association of Student Financial Aid Administrators |
02/1992 - 11/1994 Association of American Medical Colleges |
2012 - 2015 Phi Kappa Phi Honor Society |
2013 - 2021 Golden Key International Honor Society |
03/2015 - 2019 National Council of University Research Administrators |
06/2015 - Present American Society for Transplant and Cellular Therapy (ASTCT) (Member) |
07/2018 - Present American Society for Hematology (ASH) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
10/2015 - Present Journal of the American Medical Society, Oncology |
07/2022 - Present Future Oncology, Journal of Future Medicine |
07/2022 - Present American Society for Transplantation and Cellular Therapy |
Ad-Hoc Reviewer |
07/2023 - Present Clinical-Translational Science Review Committee, Cancer Center, Medical College of Wisconsin |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
05/2020 - Present Member, CIBMTR Joint Affiliation Board, Center for International Blood and Marrow Transplant Research |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
03/2013 - Present Member, Annual Tandem Meetings Scientific Organizing Committee, CIBMTR and American Society of Transplantation and Cellular Therapy |
2013 - 2015 Co-Chair, Data Management Task Force, Foundation for the Accreditation of Cellular Therapy |
2015 - Present Member, FACT Data Audit Committee, Foundation for the Accreditation of Cellular Therapy |
2016 Member, Program Selection Committee, Academy Health 2017 Datapalooza Conference |
2018 - Present Member, Immuno-Oncology Translation Network Steering Committee, National Institute of Health |
2019 - 2020 Member, Sub-committee for Data Access and Sharing, Cure Sickle Cell Initiative, National Institutes of Health |
01/2020 - 01/2021 Member, Cure Sickle Cell Initiative Common Data Elements Project, National Institutes of Health |
03/2021 - 11/2023 Member, AcCellerate Forum Planning Committee, ASTCT/CIBMTR |
07/2021 - Present Member, Tandem Meetings Senior Leadership Team, ASTCT/CIBMTR |
08/2022 - 05/2023 Member, ASH-HHS Sickle Cell Disease Registry Leaders' Data Roundtable, American Society of Hematology, Department of Health and Human Services |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
Regional |
Patricia Steinert, Assessing the Quality of Hip Fracture Treatment in Louisiana Hospitals, Louisiana Health Care Review Symposium, Baton Rouge, 05/1996 |
Patricia Steinert, Predictors of Healthcare Cost in a Wisconsin Acute Leukemia Population: Utilization of a State-Level All Payer Claims Database, Wisconsin Health Information Organization Symposium, Madison, WI, 11/2012 |
Patricia Steinert, Predictors of Healthcare Cost in a Wisconsin Acute Leukemia Population: Utilization of a State-Level All Payer Claims Database, UWM College of Health Sciences Fall Research Symposium, Milwaukee, WI, 12/2012 |
Patricia Steinert, Data Security Panel Discussion, Versiti IS Tech Summit, Virtual, 09/2021 |
National |
Patricia Steinert, KGF Long Term Follow Up Study Overview and Update, NMDP Council Meeting, Minneapolis, MN, 11/2008 - 2011 |
Patricia Steinert, KGF Long Term Follow Up Study Roundtable Discussion, ASBMT-CIBMTR Tandem Meetings, Tampa Florida, San Diego CA, Honolulu Hi, 2009 - 2011 |
Patricia Steinert, Foundation for the Accreditation of Cellular Therapy (FACT) Data Management Task Force Recommendations, CIBMTR Advisory Meeting at the Tandem Meetings, San Diego CA, 02/2015 |
Patricia Steinert, Value Assessment in Engineered T-Cell Therapies, ASBMT Forum Workshop, Boston, MA, 05/2017 |
Patricia Steinert, ASBMT Consensus Conference on CAR-T Toxicities, ASBMT Consensus Workshop, Chicago, IL, 06/2018 |
Patricia Steinert, Developing a Code of Conduct for the EU GDPR, Mapping the Commitments of the US Trial Sites and Research Sponsors Workshop, New York, NY, 11/2018 |
Patricia Steinert, Perspectives on Long Term Follow Up for Cellular Therapy, America's Health Insurance Plans Conference, Virtual, 06/2021 |
Patricia Steinert, PhD, MBA, Center Specific Outcomes from a Data Collection/Analysis Perspective, AcCellerate Forum, Virutal, 11/2022 |
Patricia Steinert, PhD, MBA, Participant, ASH-HHS Sickle Cell Disease (SCD) Registry Leaders Round Table discussion, Washington, DC, 11/2022 |
Patricia Steinert, PhD, MBA, CIBMTR Overview, Sickle Cell HSCT Long Term Follow Up, ASH-HHS Sickle Cell Disease Registry Leaders' Roundtable 2, CIBMTR Overview, Virtual, 03/2023 |
Patricia Steinert, PhD, MBA, Data Partnerships and Possibilities: Beyond the CIBMTR Working Committees, ASTCT CIBMTR Tandem Meetings, San Antonio, TX, 02/2024 - Present |
Patricia Steinert, PhD, MBA, Clinical Trial Optimization Panel, NextGen Therapies Industry Working Group Meeting, Deloitte University, Dallas TX, 03/2024 |
Patricia Steinert, PhD, MBA, CIBMTR Contemporaneous Controls, NHLBI CureSCI Long Term Follow Up In-Person meeting, Washington DC, 03/2024 - Present |
International |
Patricia Steinert, CAR-T Cell Therapy Registries Workshop, European Medicines Agencies (EMA) Workshop, London, England, 09/2018 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
06/2013 - Present Member, CIBMTR Advisory, Executive and Nominating Committees, Center for International Blood and Marrow Transplant Research, Medicine, Medical College of Wisconsin |
07/2021 - Present Member, Institutional Review Board Committee #3, Office of Research, Medical College of Wisconsin |
08/2022 - Present Member, Cancer Research Building Planning User Group, Clinical Cancer Center, Medical College of Wisconsin |
11/2023 - Present Member, CIBMTR Statistical Director Search Committee, Biostatistics, Data Science Institute, Medical College of Wisconsin |
01/2024 - Present Member, Data Science Institute Strategic Planning Committee, Data Science Institute, Medical College of Wisconsin |
EXTRAMURAL TEACHING: |
Continuing Medical Education |
02/2014 Patricia Steinert, The Breadth and Depth of CIBMTR, ASBMT-CIBMTR Tandem Meeting, San Diego, CA, 2/2014. |
01/2018 Transplant Coordinators Association, The Role of CIBMTR in the Hematopoietic Cell Transplant World |
Graduate Student Education |
01/2011 - 05/2011 Teaching Assistant, University of Wisconsin-Milwaukee, College of Health Sciences graduate level course on Population Health Outcomes. |
PROGRAMMATIC DEVELOPMENTS: |
Research Programs |
2015 - 2021 Expansion of registry operations including necessary governance, resource allocation, strategy and process quality assurance and control |
2017 - 2021 Registry operations expansion to support FDA Post Authorization Safety Studies specific to cellular therapies (CART) |
2018 Established validated CIBMTR process and systems audit structure required by HRSA |
2018 Established a CIBMTR Corporate Office to support industry sponsored research |
2018 Developed the CIBMTR European Union Data Transmission and Sharing Agreement |
2019 Directed registry expansion supporting gene therapy outcomes research |
2021 Key Leader in renegotiation of the NMDP/MCW CIBMTR Affiliation Agreement |
03/2022 - Present Registry to Registry Data Sharing Network Infrastructure Expansion |
COMMUNITY SERVICE ACTIVITIES: |
2013 - Present Training Resources for Clinical Research Professionals and Data Management including new Data Manager Onboarding, Forms Instruction Manuals, Online data management training modules. |
2016 - Present Dataset Sharing tools and applications including web-based Data Back to Centers, Center Performance Analytics, Data for RFI, Partnershare, Data Operations Dashboard and COVID Webpage. |
2016 - Present Online Calculators including Patient One Year Survival, Disease Risk Index Assessment Tool and Veno-Occlusive Disease of the Liver Risk Calculator |
2021 Volunteer: MCW COVID vaccination clinic |
GLOBAL HEALTH ACTIVITIES: |
2013 - Present Development and ongoing delivery of data to the Canadian Transplant Registry |
2015 - Present Ongoing harmonization of data variables between CIBMTR and the European Society for Blood and Marrow Transplantation |
2017 - Present In support of the Brazilian Hematopoietic Stem Cell Transplant Registry, translation of data collection forms to Portuguese. |
2018 - Present In collaboration with the Japanese Data Center for Hematopoietic Cell Transplantation, translation of cellular therapy forms to Japanese and systems privacy modifications to allow for secure transfer of data compliant with Japanese international data transmission requirements. |
MEDICAL COLLEGE OF WISCONSIN STAFF MENTORED: |
01/2023 - Present Shanti Kozuch, MCW, Institutional Review Board Coordinator
|
MEDICAL COLLEGE OF WISCONSIN STUDENT MENTORED: |
07/2023 - Present Carlos Litovich,MCW, PhD student, CIBMTR Program Manager |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Steinert, P, Cisler, R. Understanding Health Care Costs in a Wisconsin Acute Leukemia Population. Journal of Patient Centered Research and Reviews, 2016, Vol. 3, Issue 3, p142-149. |
2. Meyer C, Unekis M, Burns L, Denzen E, Farnia S, Steinert P, Saber W, Murphy E, Mau LW. Lessons Learned from Merging CIBMTR Data and CMS Medicare Claims Data. Biology of Blood and Marrow Transplantation, 2017, Vol 23, Issue 3, Supplement p S414-S415. |
3. Mau LW, Meyer C, Burns L, Saber W, Steinert P, Vanness D, Preussler J, Silver A, Leppke S, Murphy E, Denzen E. Healthcare Reimbursement and Service Utilization for One Year of Post-Allogeneic Hematopoietic Cell Transplantation (allHCT) Care for Medicare Beneficiaries Ages 65 and Older with Acute Myeloid Leukemia. Blood, 2017, Vol 130, Issue Suppl 1, p4695. |
4. Duncan C, St Martin A, Perez W, Steinert P, Zhang MJ, Chirnomas D, Hoang C, Loberiza F, Saber W. Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, Vol 24, Issue 3, Supplement, pS302. |
5. Vanness D, Preussler J, Burns L, Denzen E, Leppke S, Majhail N, Mupfudze T, Saber W, Silver A, Steinert P, Mau LW. Estimating Propensity Scores for the Receipt of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Outcomes Research Using Claims Data: A Machine Learning Approach. Biology of Blood and Marrow Transplantation, 2018, Vol 24, Issue 3, pS304-S305. |
6. Jaglowski S, Hu ZH, Zhang Y, Kamdar M, Ghosh M, Lulla P, Sasine J, Perales MA, Hematti P, Nikiforow S, Steinert P, Jeschke M, Yi L, Chawla R, Pacaud L, Horowitz M, Bleickardt E, Pasquini M. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood, 2019, Vol. 134, (Supplement_1): 766. |
7. Pasquini M, Locke F, Herrera A, Siddiqi T, Ghobadi A, Komanduri K, Hu ZH, Dong H, Hematti P, Nikiforow S, Steinert P, Purdum A, Horowitz M, Hooper M, Kawashima J, Jacobson C. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood, 2019, Vol. 134 (Supplement_1): 764. |
8. Mau LW, Meyer C, Burns L, Saber W, Steinert P, Vanness D, Preussler J, Silver A, Leppke S, Murphy E, Denzen E. Reimbursement, Utilization, and One-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries with Acute Myeloid Leukemia. JNCI Cancer Spectrum, 2019, https://doi.org/10.1093/jncics/pkz048. |
9. Ho V, St. Martin A, Perez, W, Steinert P, Zhang MJ, Chirnomas D, Hoang C, Loberiza F, Saber W. Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2020, https://doi.org/10.1016/j.bbmt.2019.12.763. |
10. Saber W, Zhang MJ, Steinert P, Chen M, Horowitz MM. The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children. Biol Blood Marrow Transplant. 2016 Aug;22(8):1460-1466. PMCID: PMC4949099 |
11. Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, Deeg HJ. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018 Aug 28;2(16):2095-2103. PMCID: PMC6113615 |
12. Mau LW, Meyer C, Burns LJ, Saber W, Steinert P, Vanness DJ, Preussler JM, Silver A, Leppke S, Murphy EA, Denzen E. Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia. JNCI Cancer Spectr. 2019 Dec;3(4):pkz048. PMCID: PMC6845850 |
13. Ho VT, Martin AS, Pérez WS, Steinert P, Zhang MJ, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2020 May;26(5):884-892. PMCID: PMC7439134 |
14. Mau LW, Preussler JM, Burns LJ, Leppke S, Majhail NS, Meyer CL, Mupfudze T, Saber W, Steinert P, Vanness DJ. Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach. Pharmacoeconomics. 2020 May;38(5):515-526. PMCID: PMC7194165 |
15. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. PMCID: PMC7404814 |
16. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-5424. PMCID: PMC7656920 |
17. Duncan C, St Martin A, Pérez WS, Steinert P, Zhang MJ, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W. Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer. 2021 Aug;68(8):e29067. PMCID: PMC8324076 |
18. Mupfudze TG, Meyer C, Preussler JM, Mau LW, Bolon YT, Steinert P, Arnold SD, Saber W, Krishnamurti L. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplant Cell Ther. 2021 Aug;27(8):685.e1-685.e8. PMCID: PMC8680220 |
19. Saber W, Steinert P, Zhang MJ, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales MA, Forman S, Champlin R, Langston A, Rudebeck M, Horowitz M. A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. Transplant Cell Ther. 2021 Oct;27(10):837.e1-837.e10. PMCID: PMC8606163 |
20. St Martin A, Hebert KM, Serret-Larmande A, Jouhet V, Hughes E, Stedman J, DeSain T, Pillion D, Lyons JC, Steinert P, Avillach P, Eapen M. Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population. Transplant Cell Ther. 2022 Jun;28(6):325.e1-325.e7. PMCID: PMC9198002 |
21. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. PMCID: PMC9840526 |
22. Mau LW, Preussler JM, Meyer CL, Senneka MK, Wallerstedt S, Steinert P, Khera N, Saber W. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia. Transplant Cell Ther. 2022 Dec;28(12):852-858. PMCID: PMC10183994 |
23. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182, (S1083879120302251), (10.1016/j.bbmt.2020.04.013)] Transplantation and Cellular Therapy. October 2022;28(10):715-716. |
24. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022 Oct;28(10):715-716. |
25. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. PMCID: PMC10239334 |
Abstracts |
1. Steinert, P. Predictors of Healthcare Cost in a Wisconsin Acute Leukemia Population: Utilization of a State-Level All Payer Claims Database, UWM College of Health Sciences Fall Research Symposium, poster presentation, December 2012. |
2. Saber W, Steinert P, Zhang MJ, Chen M. Impact of Palifermin Use on Pediatric Patients Hematopoietic Cell Transplant Outcomes. Poster session presented at: American Society of Clinical Oncology; 2014 May 30-June 3; Chicago, IL. |
3. Meyer C, Unekis M, Burns, L, Denzen E, Preussler J, Steinert P, Saber W, Murphy E, Mau LW. Lessons Learned from Merging CIBMTR Data and CMS Medicare Claims Data; Presented at the ASBMT/CIBMTR Tandem Meetings, February 2017, Orlando FL. |
4. Mau L.W, Meyer C, Burns L, Saber W, Steinert P, Vanness D, Preussler J, Silver A, Luepke S, Denzen E. Healthcare Reimbursement and Service Utilization for One Year of Post-Allogeneic Hematopoietic Cell Transplantation (alloHCT) Care for Medicare Beneficiaries Ages 65 and Older with Acute Myeloid Leukemia, American Society of Hematology Annual Meeting, December 2017, Atlanta, GA and the Academy Health Annual Research Meeting, June 2018, Seattle, WA. |
5. Ho V, St. Martin A, Perez W, Steinert P, Zhang MJ, Chirnomas D, Hoang C, Loberiza F, Saber W. Characterization of Veno-Occlusive Disease (VOD) in Adult Patients with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) Before Allogeneic Stem Cell Transplant (SCT). Presented at the BMT Tandem Meetings, February 2018, Salt Lake City, Utah, the European Society for Blood and Marrow Transplantation Annual Meeting, March 2018, Lisbon, Portugal and the Canadian Blood and Marrow Transplant Group Annual Meeting, Ottawa, Canada, June 2018. |
6. Duncan C, St. Martin A, Perez W, Steinert P, Zhang MJ, Chirnomas D, Hoang C, Loberiza F, Saber W. Veno-Occlusive Disease (VOD) Characteristics in Pediatric Patients with Acute Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) Before Allogeneic Stem Cell Transplant (SCT). Presented at the BMT Tandem Meetings, February 2018, Salt Lake City, Utah and the European Society for Blood and Marrow Transplantation Annual Meeting, March 2018, Lisbon, Portugal and the Canadian Blood and Marrow Transplant Group Annual Meeting, Ottawa, Canada, June 2018. |
7. Pasquini M, Hu ZH, Zhang Y, Grupp S, Hematti P, Jaglowski S, Keating A, Nikiforow S, Phillips C, Pulsipher M, Shah S, Steinert P, Yanik G, Wang H, Horowitz M, Bleikardt E. Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, Volume 19, Supplement 1, S267. |
8. St. Martin A, Hebert K, Serret-Larmande A, Jouhet V, Hughes E, Stedman JP, DeSain T, Pillon D, Lyons J, Steinert P, Avillach P, Eapen M. Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least two-Years after Transplant. 63rd ASH Annual Meeting and Exposition, Atlanta, Georgia, December 2021. |
9. Mau LW, Preussler J, Meyer C, Senneka M, Wallerstedt S, Steinert P, Khera N, Saber W. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia. 63rd ASH Annual Meeting and Exposition, Atlanta, Georgia, December 2021. |
